HMGCR and type 2 diabetes mellitus: Multiple randomized clinical trials have shown that inhibiting HMG-CoA reductase with statins increases the risk of developing new-onset type 2 diabetes in a dose-dependent manner, although the mechanism driving this association has remained elusive54–56.